Long-Term Follow-up of Subjects Who Were Treated With ST-920

NCT05039866 · tracked via the Priya Life Science UK tracker

Sponsor

Sangamo Therapeutics

Phase

Observational

Started

2021-08-16

Last updated

2026-08-20

Condition(s) studied

Fabry DiseaseFabry Disease, Cardiac Variant

Investigational drug(s) / intervention(s)

ST-920

ST-920: No study drug is administered in this study. Subjects who received ST-920 in a separate parent trial will be evaluated in this trial for long-term safety.

Study summary

Long-term follow-up of subjects who received ST-920 in a previous trial (ST-920-201) and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled subjects will be followed for a total of up to 5 years following ST-920 infusion.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Subjects who received ST-920 therapy in a separate parent trial * Subjects who have consented to participate in this LTFU study. Exclusion Criteria: -This study has no exclusion criteria

Primary outcome measure(s)

To evaluate long-term safety of ST-920 — 4 years
To evaluate long-term safety of ST-920 by assessment of incidence and severity of adverse events (AEs)

Trial sites (13)

Facility	City	Region
University of California, Irvine	Irvine	California
University of South Florida	Tampa	Florida
Emory University School of Medicine	Atlanta	Georgia
University of Iowa Hospital and Clinics	Iowa City	Iowa
University of Minnesota Medical Center	Minneapolis	Minnesota
Mt. Sinai Hospital	New York	New York
Cincinnati Children's Hospital Medical Center	Cincinnati	Ohio
Lysosomal & Rare Disorders Research & Treatment Center (LDRTC)	Fairfax	Virginia
The Royal Melbourne Hospital	Parkville	Victoria
M.A.G.I.C. Clinic Ltd.	Calgary	Alberta
University Hospital of Würzburg	Würzburg	Germany
Addenbrooke's Hospital	Cambridge	United Kingdom
Royal Free Hospital	London	United Kingdom

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05039866 on ClinicalTrials.gov ↗ ← All trials in the UK